Synthesis process of trityl olmesartan medoxomil
By generating intermediate A under alkaline conditions and purifying it using a catalyst and silica gel column chromatography, the problem of removing impurities and byproducts in the synthesis of triphenylmethylolmesartan medoxomil was solved, thus improving the purity of the product.
Patent Information
- Application Number
- CN202411117597.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-15
- Publication Date
- 2024-11-29
AI Technical Summary
In the existing technology, impurities and byproducts are difficult to remove effectively during the synthesis of triphenylmethylolmesartan medoxomil, which affects the purity of the product.
Intermediate A was generated by reaction under alkaline conditions. Impurities and byproducts were removed by purification using a catalyst and silica gel column chromatography. The solvent and reagent ratios were optimized to improve purity.
It effectively removes impurities and byproducts in the reaction process, improving the purity of triphenylmethylolmesartan medoxomil.
Abstract
Description
Technical Field
[0001] The present application relates to the technical field of the synthesis of olmesartan medoxomil intermediates, and in particular to a synthesis process of trityl olmesartan medoxomil. Background Art
[0002] Olmesartan medoxomil is more effective than losartan and other earlier sartan drugs. It is an ideal antihypertensive drug with good efficacy for all types of hypertension. Its outstanding feature is its long half-life, which can effectively control blood pressure within one day, so it is more convenient to take. At the same time, compared with other angiotensin receptor antagonist drugs, it has the advantages of small dosage, rapid onset, stronger and more lasting antihypertensive effect, and low incidence of adverse reactions. As an important intermediate in the synthesis of olmesartan medoxomil, trityl olmesartan medoxomil determines the quality of the final olmesartan medoxomil. Usually, when synthesizing trityl olmesartan medoxomil, it often contains some impurities, which will affect the purity of the trityl olmesartan medoxomil. Summary of the invention
[0003] In order to improve the purity of the intermediate trityl olmesartan medoxomil, the present application provides a synthesis process of trityl olmesartan medoxomil.
[0004] The present application provides a synthesis process of trityl olmesartan medoxomil, which adopts the following technical scheme: A synthesis process of trityl olmesartan medoxomil comprises the following steps: Preparation of intermediate A: 2-propyl-4-(1-hydroxy-1-methylethyl)imidazole-5-carboxylic acid ethyl ester (alcohol ester) and 5-(4-bromomethyl-1,1-biphenyl-2-yl)-1-trityl tetrazole are added to solvent A, and then a strong base is added, and the mixture is stirred and mixed evenly to obtain a mixture A; the mixture A is heated to react, and after the reaction is completed, the temperature is reduced, and the mixture is evaporated under reduced pressure to obtain a mixture B; the mixture B is heated, and then a strong base solution is added to react, extracted, cooled and crystallized, and filtered, and the filter cake is added to solvent A again, filtered again, and dried to obtain intermediate A; Synthesis of trityl olmesartan medoxomil: intermediate A and weak acid salt are added to solvent B, stirred and mixed evenly to obtain mixture C; then catalyst and 4-chloromethyl-5-methyl-1,3-dioxol-2-one are added to mixture C to react, filtered, and the filtrate is purified by column chromatography using silica gel as the stationary phase to obtain an eluent, and vacuum rotary evaporation is performed. Finally, solvent A is added, stirred and crystallized, filtered, and the filter cake is dried to obtain trityl olmesartan medoxomil.
[0005] By adopting the above technical scheme, propyl-4-(1-hydroxy-1-methylethyl) imidazole-5-carboxylic acid ethyl ester (alcohol ester) and 5-(4-bromomethyl-1,1-biphenyl-2-yl)-1-trityl tetrazole are first reacted under alkaline conditions to obtain intermediate A; then intermediate A, weak acid salt and 4-chloromethyl-5-methyl-1,3-dioxol-2-one are reacted under the action of a catalyst, and then column chromatography with silica gel as the stationary phase is used for purification, which can effectively remove impurities and by-products in the reaction process, thereby improving the purity of the product trityl olmesartan medoxomil.
[0006] In a specific embodiment, in the preparation step of the intermediate A, the weight ratio of the 2-propyl-4-(1-hydroxy-1-methylethyl)imidazole-5-carboxylic acid ethyl ester (alcohol ester), the 5-(4-bromomethyl-1,1-biphenyl-2-yl)-1-trityltetrazole, the solvent A, and the strong base is 1:(2.5-2.6):(26-27):(0.2-0.3).
[0007] By adopting the above technical scheme, the coordination of 2-propyl-4-(1-hydroxy-1-methylethyl)imidazole-5-carboxylic acid ethyl ester (alcohol ester), 5-(4-bromomethyl-1,1-biphenyl-2-yl)-1-trityl tetrazole, solvent A, and strong base is further limited, so that 2-propyl-4-(1-hydroxy-1-methylethyl)imidazole-5-carboxylic acid ethyl ester (alcohol ester) and 5-(4-bromomethyl-1,1-biphenyl-2-yl)-1-trityl tetrazole can be better reacted, which is conducive to the better generation of intermediate A.
[0008] In a specific embodiment, in the intermediate A preparation step, the solvent A includes one or more of acetonitrile, ethanol, methanol, and acetone.
[0009] By adopting the above technical scheme, acetonitrile, ethanol, methanol and acetone all have good dissolving effects, among which acetonitrile is used as solvent A to reduce impurities in intermediate A, thereby improving the purity of the product trityl olmesartan medoxomil.
[0010] In a specific embodiment, in the intermediate A preparation step, the strong base includes one or more of sodium hydroxide, potassium hydroxide, and lithium hydroxide.
[0011] In a specific embodiment, in the step of preparing the intermediate A, the strong alkaline solution is a mixture of lithium hydroxide hydrate and water, and the weight ratio of the lithium hydroxide hydrate to the water is 1:(5.5-6.0).
[0012] In a specific embodiment, in the preparation step of the intermediate A, the mixed material B is heated, and then a strong alkaline solution is added to react, and then the temperature is reduced, ethyl acetate and deionized water are added, stirred, and then glacial acetic acid aqueous solution is added to adjust the system pH to 6-7, the temperature is reduced for crystallization, and suction is filtered. The filter cake is added to the solvent A again, suction is filtered again, and dried to obtain the intermediate A.
[0013] By adopting the above technical scheme, using ethyl acetate and deionized water for extraction, and then using glacial acetic acid aqueous solution to adjust the pH of the system, the mixture B can be better extracted and crystallized, thereby improving the purity of the intermediate A obtained.
[0014] In a specific embodiment, in the trityl olmesartan medoxomil synthesis step, the weight ratio of the intermediate A, the weak acid salt, and the solvent B is 1:(0.3-0.5):(5-6).
[0015] By adopting the above technical solution, the ratio of the intermediate A, the weak acid salt and the solvent B is further limited, so that the trityl olmesartan medoxomil can be better formed.
[0016] In a specific embodiment, in the trityl olmesartan medoxomil synthesis step, the weak acid salt includes one or more of potassium carbonate, potassium acetate, and sodium carbonate.
[0017] In a specific embodiment, in the trityl olmesartan medoxomil synthesis step, the catalyst includes one or more of potassium iodide, sodium iodide, and sodium chloride.
[0018] In a specific embodiment, in the trityl olmesartan medoxomil synthesis step, when the filtrate is purified by column chromatography, the eluent comprises a mixture of petroleum ether and ethyl acetate.
[0019] By adopting the above technical solution and using a composite eluent consisting of petroleum ether and ethyl acetate, the system can be better purified, thereby further improving the purity of the product trityl olmesartan medoxomil.
[0020] In summary, the present application includes at least one of the following beneficial technical effects: 1. In the present application, propyl-4-(1-hydroxy-1-methylethyl) imidazole-5-carboxylic acid ethyl ester (alcohol ester) and 5-(4-bromomethyl-1,1-biphenyl-2-yl)-1-trityl tetrazole are reacted under alkaline conditions to obtain intermediate A; then intermediate A, weak acid salt, and 4-chloromethyl-5-methyl-1,3-dioxol-2-one are reacted under the action of a catalyst, and then purified by column chromatography using silica gel as the stationary phase, which can effectively remove impurities and by-products in the reaction process, thereby improving the purity of the product trityl olmesartan medoxomil; 2. The present application further defines the combination of 2-propyl-4-(1-hydroxy-1-methylethyl)imidazole-5-carboxylic acid ethyl ester (alcohol ester), 5-(4-bromomethyl-1,1-biphenyl-2-yl)-1-trityl tetrazole, solvent A, and a strong base, which can make 2-propyl-4-(1-hydroxy-1-methylethyl)imidazole-5-carboxylic acid ethyl ester (alcohol ester) and 5-(4-bromomethyl-1,1-biphenyl-2-yl)-1-trityl tetrazole react better, which is conducive to the better formation of intermediate A; 3. In the present application, acetonitrile, ethanol, methanol and acetone all have good dissolving effects, among which acetonitrile as solvent A can reduce impurities in intermediate A, thereby improving the purity of the product trityl olmesartan medoxomil. DETAILED DESCRIPTION
[0021] The present application is further described in detail below in conjunction with embodiments.
[0022] All raw materials in the embodiments can be obtained commercially. Solvent A includes but is not limited to a mixture of one or more of acetonitrile, ethanol, methanol, and acetone, preferably acetonitrile in this application; strong base includes but is not limited to a mixture of one or more of sodium hydroxide, potassium hydroxide, and lithium hydroxide, preferably sodium hydroxide in this application; weak acid salt includes but is not limited to a mixture of one or more of potassium carbonate, potassium acetate, and sodium carbonate, preferably potassium carbonate in this application; catalyst includes but is not limited to a mixture of one or more of potassium iodide, sodium iodide, and sodium chloride, preferably sodium iodide in this application. Example
[0023] Example 1 Embodiment 1 provides a synthesis process of trityl olmesartan medoxomil, comprising the following steps: Preparation of intermediate A: 2-propyl-4-(1-hydroxy-1-methylethyl)imidazole-5-carboxylic acid ethyl ester (alcohol ester) and 5-(4-bromomethyl-1,1-biphenyl-2-yl)-1-trityl tetrazole are added to solvent A, and then a strong base is added, and the mixture is stirred and mixed to obtain a mixture A; the mixture A is heated to 70°C for reaction, and after the reaction is completed, the temperature is lowered to 40°C, and the solvent A is removed by vacuum rotary evaporation to obtain a mixture B; 1, 4-dioxane, stirred and mixed at 40°C, then dropped a strong alkali solution to react, then cooled, added ethyl acetate and deionized water, stirred, then dropped a 75% mass concentration of glacial acetic acid aqueous solution to adjust the system pH to 6-7, cooled to 10°C, crystallized, filtered, the filter cake was added to solvent A again, slurried for 40 minutes, filtered again, and the filter cake was dried at 40°C to obtain intermediate A; wherein 2-propyl-4-(1-hydroxy-1-methyl The weight ratio of 1,4-dioxane to 2-propyl-4-(1-hydroxy-1-methylethyl)imidazole-5-carboxylic acid ethyl ester (alcohol ester) is 10:1; the strong base solution is a mixture of lithium hydroxide hydrate and water, and the strong base is 1:2.5:26:0.2; the solvent A is acetonitrile; the strong base is sodium hydroxide; the ... strong base is 1:2.5:26:0.2; the strong base is acetonitrile; the strong base is sodium hydroxide; the strong base is 1:2.5:26:0.2; the strong base is acetonitrile; the strong base is sodium hydroxide; the strong base is 1:2.5:26:0.2; the strong base is acetonitrile; the strong base is sodium hydroxide; the strong base is 1:2.5:26:0.2; the strong base is 1:2.5:26:0.2; the strong base is 1:2.5:26:0.2; the strong base is 1:2.5:26:0.2; the strong base is 1:2.5:26:0.2; the strong base is 1:2.5:26:0.2; the strong base is 1:2.5:26:0.2; the strong base is 1:2.5:26:0.2; the strong base is 1:2.5:26:0.2; the strong base is 1:2 The weight ratio of lithium hydrate to water is 1:5.6; the weight ratio of strong alkali solution to 2-propyl-4-(1-hydroxy-1-methylethyl) imidazole-5-carboxylic acid ethyl ester (alcohol ester) is 4:1; the weight ratio of ethyl acetate to 2-propyl-4-(1-hydroxy-1-methylethyl) imidazole-5-carboxylic acid ethyl ester (alcohol ester) is 10.5:1; the weight ratio of deionized water to 2-propyl-4-(1-hydroxy-1-methylethyl) imidazole-5-carboxylic acid ethyl ester (alcohol ester) is 10:1; Synthesis of trityl olmesartan medoxomil: add intermediate A and weak acid salt to solvent B, stir and mix evenly at 25°C to obtain mixture C; then add catalyst to mixture C, drop 4-chloromethyl-5-methyl-1,3-dioxol-2-one to react, filter with suction, purify the filtrate by column chromatography, use silica gel as stationary phase to obtain eluent, then evaporate under reduced pressure at 40°C, finally add solvent A, stir and crystallize at 10°C, filter with suction, and dry the filter cake at 40°C to obtain trityl olmesartan medoxomil; wherein intermediate A and weak acid salt are added to solvent B, stir and crystallize at 25°C, filter with suction, and dry the filter cake at 40°C to obtain trityl olmesartan medoxomil; wherein intermediate A and weak acid salt are added to solvent B, stir and crystallize at 25°C, filter with suction, and dry the filter cake at 40°C to obtain trityl olmesartan medoxomil; The weight ratio of intermediate A, weak acid salt and solvent B is 1:0.3:5; the weak acid salt is potassium carbonate; solvent B is N,N-dimethylformamide; the weight ratio of catalyst to intermediate A is 1:8.3, and the catalyst is sodium iodide; the weight ratio of 4-chloromethyl-5-methyl-1,3-dioxol-2-one to intermediate A is 1:3.3; the eluent in column chromatography purification is a mixture of petroleum ether and ethyl acetate, and the weight ratio of petroleum ether to ethyl acetate is 1:1; the weight ratio of solvent A to intermediate A is 3.5:1; solvent A is acetonitrile.
[0024] Example 2 The difference between Example 2 and Example 1 is that intermediate A is prepared by adding 2-propyl-4-(1-hydroxy-1-methylethyl)imidazole-5-carboxylic acid ethyl ester (alcohol ester) and 5-(4-bromomethyl-1,1-biphenyl-2-yl)-1-trityl tetrazole to solvent A, then adding a strong base, stirring and mixing evenly to obtain a mixture A; heating the mixture A to 70°C for heat reaction, cooling to 40°C after the reaction is completed, and vacuum rotary evaporation to remove solvent A to obtain a mixture B; adding 1,4-dioxane to the mixture B, stirring and mixing evenly at 40°C, then dropping a strong base solution for reaction, and then Cooling, adding ethyl acetate and deionized water, stirring, then dripping 75% mass concentration of glacial acetic acid aqueous solution to adjust the system pH to 6-7, cooling to 10°C, crystallizing, filtering, adding the filter cake to solvent A again, beating for 40 minutes, filtering again, and drying the filter cake at 40°C to obtain intermediate A; wherein the weight ratio of 2-propyl-4-(1-hydroxy-1-methylethyl)imidazole-5-carboxylic acid ethyl ester (alcohol ester), 5-(4-bromomethyl-1,1-biphenyl-2-yl)-1-trityl tetrazole, solvent A, and strong base is 1:2.55:26.5:0.25; the remaining steps are consistent with Example 1.
[0025] Example 3 The difference between Example 3 and Example 1 is that intermediate A is prepared by adding 2-propyl-4-(1-hydroxy-1-methylethyl)imidazole-5-carboxylic acid ethyl ester (alcohol ester) and 5-(4-bromomethyl-1,1-biphenyl-2-yl)-1-trityl tetrazole to solvent A, then adding a strong base, stirring and mixing evenly to obtain a mixture A; heating the mixture A to 70° C. to keep the mixture warm for reaction, cooling to 40° C. after the reaction is completed, and vacuum rotary evaporation is performed to remove solvent A to obtain a mixture B; adding 1,4-dioxane to the mixture B, stirring and mixing evenly at 40° C., and then dropping a strong base solution to react, Then cool down, add ethyl acetate and deionized water, stir, then add dropwise 75% mass concentration of glacial acetic acid aqueous solution to adjust the system pH to 6-7, cool down to 10°C, crystallize, filter, add the filter cake into solvent A again, slurry for 40 minutes, filter again, and dry the filter cake at 40°C to obtain intermediate A; wherein the weight ratio of 2-propyl-4-(1-hydroxy-1-methylethyl)imidazole-5-carboxylic acid ethyl ester (alcohol ester), 5-(4-bromomethyl-1,1-biphenyl-2-yl)-1-trityl tetrazole, solvent A, and strong base is 1:2.6:27:0.3; the remaining steps are consistent with Example 1.
[0026] Example 4 The difference between Example 4 and Example 2 is that, in the synthesis of trityl olmesartan medoxomil: intermediate A and weak acid salt are added to solvent B, and the mixture is stirred and mixed evenly at 25°C to obtain a mixture C; then a catalyst is added to the mixture C, 4-chloromethyl-5-methyl-1,3-dioxol-2-one is added dropwise to react, filtered, and the filtrate is purified by column chromatography, using silica gel as a stationary phase to obtain an eluent, and then vacuum rotary evaporation is performed at 40°C, and finally solvent A is added, stirred and crystallized at 10°C, filtered, and the filter cake is dried at 40°C to obtain trityl olmesartan medoxomil; wherein the weight ratio of intermediate A, weak acid salt, and solvent B is 1:0.4:5.5; and the remaining steps are consistent with Example 2.
[0027] Example 5 The difference between Example 5 and Example 2 is that trityl olmesartan medoxomil is synthesized by adding intermediate A and weak acid salt to solvent B, stirring and mixing at 25°C to obtain a mixture C; then adding a catalyst to the mixture C, adding 4-chloromethyl-5-methyl-1,3-dioxol-2-one dropwise to react, filtering, and purifying the filtrate by column chromatography, using silica gel as a stationary phase to obtain an eluent, and then vacuum evaporating at 40°C, and finally adding solvent A, stirring and crystallizing at 10°C, filtering, and drying the filter cake at 40°C to obtain trityl olmesartan medoxomil; wherein the weight ratio of intermediate A, weak acid salt, and solvent B is 1:0.5:6; and the remaining steps are consistent with Example 2.
[0028] Example 6 The difference between Example 6 and Example 4 is that the eluent in the column chromatography purification is petroleum ether; the remaining steps are consistent with Example 4.
[0029] Example 7 The difference between Example 7 and Example 4 is that the eluent in the column chromatography purification is ethyl acetate; the remaining steps are consistent with Example 4.
[0030] Comparative Example Comparative Example 1 Comparative Example 1 provides a synthesis process of trityl olmesartan medoxomil, comprising the following steps: Preparation of intermediate A: 2-propyl-4-(1-hydroxy-1-methylethyl) imidazole-5-carboxylic acid ethyl ester (alcohol ester) and 5-(4-bromomethyl-1,1-biphenyl-2-yl)-1-trityl tetrazole are added to solvent A, and then a strong base is added, and the mixture is stirred and mixed evenly to obtain a mixture A; the mixture A is heated to 70°C for reaction, and after the reaction is completed, the mixture is cooled to 40°C, ethyl acetate and deionized water are added, and the mixture is stirred, and then a 75% mass concentration of glacial acetic acid aqueous solution is added dropwise to adjust the pH of the system to 6-7, and the mixture is cooled to 10°C, crystallized, and filtered, and the filter cake is added to solvent A again, slurried for 40 minutes, filtered again, and the filter cake is dried at 40°C to obtain an intermediate A; wherein 2-propyl-4-(1-hydroxy-1-methylethyl) imidazole-5-carboxylic acid ethyl ester (alcohol ester), 5-(4-bromomethyl-1,1-biphenyl-2-yl)-1-trityl tetrazole are added to solvent A, and a strong base is added, and the mixture is stirred and mixed evenly to obtain a mixture A; and the mixture A is heated to 70°C for reaction, and after the reaction is completed, the mixture is cooled to 40°C, ethyl acetate and deionized water are added, and the mixture is stirred, and then a 75% mass concentration of glacial acetic acid aqueous solution is added dropwise to adjust the pH of the system to 6-7, and the mixture is cooled to 10°C, crystallized, and filtered, and the filter cake is added to solvent A again, slurried for 40 minutes, filtered again, and the filter cake is dried at 40°C to obtain an intermediate A; wherein 2-propyl-4-(1-hydroxy-1-methyl -yl)-1-trityl tetrazole, solvent A, and strong base are in a weight ratio of 1:2.5:26:0.2; solvent A is acetonitrile; strong base is sodium hydroxide; the weight ratio of 1,4-dioxane to 2-propyl-4-(1-hydroxy-1-methylethyl)imidazole-5-carboxylic acid ethyl ester (alcohol ester) is 10:1; the strong base solution is a mixture of lithium hydroxide hydrate and water, and the weight ratio of lithium hydroxide hydrate to water is 1:5.6 ; The weight ratio of the strong base solution to ethyl 2-propyl-4-(1-hydroxy-1-methylethyl) imidazole-5-carboxylate (alcohol ester) is 4:1; the weight ratio of ethyl acetate to ethyl 2-propyl-4-(1-hydroxy-1-methylethyl) imidazole-5-carboxylate (alcohol ester) is 10.5:1; the weight ratio of deionized water to ethyl 2-propyl-4-(1-hydroxy-1-methylethyl) imidazole-5-carboxylate (alcohol ester) is 10:1; Synthesis of trityl olmesartan medoxomil: intermediate A and weak acid salt are added to solvent B, and stirred and mixed evenly at 25°C to obtain mixture C; then a catalyst is added to mixture C, 4-chloromethyl-5-methyl-1,3-dioxol-2-one is added dropwise to react, filtered, ethyl acetate and saturated brine are added to the filtrate for extraction, the filtrate is allowed to stand for stratification, the organic layer is washed, dried over anhydrous sodium sulfate, and then evaporated under reduced pressure at 40°C, and finally solvent A is added, stirred and crystallized at 10°C, filtered, and the filter cake is dried at 40°C to obtain trityl olmesartan medoxomil. Sartan ester; wherein the weight ratio of intermediate A, weak acid salt and solvent B is 1:0.3:5; the weak acid salt is potassium carbonate; solvent B is N,N-dimethylformamide; the weight ratio of catalyst to intermediate A is 1:8.3, and the catalyst is sodium iodide; the weight ratio of 4-chloromethyl-5-methyl-1,3-dioxole-2-one to intermediate A is 1:3.3; the weight ratio of solvent A to intermediate A is 3.5:1; solvent A is acetonitrile; the weight ratio of ethyl acetate to intermediate A is 5.8:1; the weight ratio of saturated brine to intermediate A is 7.5:1.
[0031] Performance Testing Purity Testing: The trityl olmesartan medoxomil products in the embodiments and comparative examples were analyzed by high performance liquid chromatography to obtain the purity.
[0032] Table 1 Trityl Olmesartan Medoxomil Product Performance Test Results sample purity(%) Example 1 99.7 Example 2 99.8 Example 3 99.7 Example 4 99.9 Example 5 99.8 Example 6 99.8 Example 7 99.8 Comparative Example 1 99.5 In combination with Example 1 and Comparative Example 1, the purity of the product trityl olmesartan medoxomil obtained in Example 1 is relatively high. It can be seen that by using the preparation method in the present application, when preparing intermediate A using 2-propyl-4-(1-hydroxy-1-methylethyl) imidazole-5-carboxylic acid ethyl ester (alcohol ester) and 5-(4-bromomethyl-1,1-biphenyl-2-yl)-1-trityl tetrazole, adding a strong base in batches can improve the quality of the intermediate A obtained, and then when synthesizing trityl olmesartan medoxomil, column chromatography is used for purification, which can effectively remove impurities and by-products in the reaction process, thereby improving the purity of the product trityl olmesartan medoxomil.
[0033] In combination with Examples 1-3, the purity of the product trityl olmesartan medoxomil obtained in Example 2 is the highest. It can be seen that when intermediate A is prepared using 2-propyl-4-(1-hydroxy-1-methylethyl)imidazole-5-carboxylic acid ethyl ester (alcohol ester) and 5-(4-bromomethyl-1,1-biphenyl-2-yl)-1-trityl tetrazole, the ratio of 2-propyl-4-(1-hydroxy-1-methylethyl)imidazole-5-carboxylic acid ethyl ester (alcohol ester), 5-(4-bromomethyl-1,1-biphenyl-2-yl)-1-trityl tetrazole, solvent A, and strong base in Example 2 is optimal, so that the quality of intermediate A is higher.
[0034] In combination with Example 2, Example 4 and Example 5, the purity of the product trityl olmesartan medoxomil obtained in Example 4 is the highest. It can be seen that when synthesizing trityl olmesartan medoxomil, the ratio of intermediate A, weak acid salt and solvent B in Example 4 is optimal, so that the obtained product trityl olmesartan medoxomil has the highest purity.
[0035] In combination with Example 4, Example 6 and Example 7, the purity of the product trityl olmesartan medoxomil obtained in Example 4 is the highest. It can be seen that when synthesizing trityl olmesartan medoxomil and purifying it by column chromatography, the eluent is preferably a complex composed of petroleum ether and ethyl acetate, which has a better elution effect on the system, thereby improving the purity of the product trityl olmesartan medoxomil.
[0036] This specific embodiment is merely an explanation of the present application and is not a limitation of the present application. After reading this specification, those skilled in the art may make modifications to the present embodiment without any creative contribution as needed. However, as long as it is within the scope of the claims of the present application, it shall be protected by the patent law.
Claims
1. A synthesis process for trityl olmesartan medoxomil, characterized in that: The following steps are involved: Preparation of intermediate A: 2-propyl-4-(1-hydroxy-1-methylethyl)imidazole-5-carboxylic acid ethyl ester (alcohol ester) and 5-(4-bromomethyl-1,1-biphenyl-2-yl)-1-trityl tetrazole are added to solvent A, and then a strong base is added, and the mixture is stirred and mixed evenly to obtain a mixture A; the mixture A is heated to react, and after the reaction is completed, the temperature is reduced, and the mixture is evaporated under reduced pressure to obtain a mixture B; the mixture B is heated, and then a strong base solution is added to react, extracted, cooled and crystallized, and filtered, and the filter cake is added to solvent A again, filtered again, and dried to obtain intermediate A; Synthesis of trityl olmesartan medoxomil: intermediate A and weak acid salt are added to solvent B, stirred and mixed evenly to obtain mixture C; then catalyst and 4-chloromethyl-5-methyl-1,3-dioxol-2-one are added to mixture C to react, filtered, and the filtrate is purified by column chromatography using silica gel as the stationary phase to obtain an eluent, and vacuum rotary evaporation is performed. Finally, solvent A is added, stirred and crystallized, filtered, and the filter cake is dried to obtain trityl olmesartan medoxomil.
2. A synthesis process for trityl olmesartan medoxomil according to claim 1, characterized in that: In the intermediate A preparation step, the weight ratio of the 2-propyl-4-(1-hydroxy-1-methylethyl)imidazole-5-carboxylic acid ethyl ester (alcohol ester), the 5-(4-bromomethyl-1,1-biphenyl-2-yl)-1-trityltetrazole, the solvent A, and the strong base is 1:(2.5-2.6):(26-27):(0.2-0.3).
3. A synthesis process for trityl olmesartan medoxomil according to claim 2, characterized in that: In the intermediate A preparation step, the solvent A includes one or more of acetonitrile, ethanol, methanol, and acetone.
4. A synthesis process for trityl olmesartan medoxomil according to claim 2, characterized in that: In the step of preparing the intermediate A, the strong base includes one or more of sodium hydroxide, potassium hydroxide, and lithium hydroxide.
5. A synthesis process for trityl olmesartan medoxomil according to claim 2, characterized in that: In the intermediate A preparation step, the strong alkaline solution is a mixture of lithium hydroxide hydrate and water, and the weight ratio of the lithium hydroxide hydrate to the water is 1: (5.5-6.0).
6. A synthesis process for trityl olmesartan medoxomil according to claim 2, characterized in that: In the preparation step of the intermediate A, the mixed material B is heated, and then a strong alkaline solution is added to react, and then the temperature is reduced, ethyl acetate and deionized water are added, stirred, and then an aqueous glacial acetic acid solution is added to adjust the system pH to 6-7, the temperature is reduced for crystallization, and suction is filtered. The filter cake is added to the solvent A again, suction is filtered again, and dried to obtain the intermediate A.
7. A synthesis process for trityl olmesartan medoxomil according to claim 1, characterized in that: In the trityl olmesartan medoxomil synthesis step, the weight ratio of the intermediate A, the weak acid salt, and the solvent B is 1: (0.3-0.5): (5-6).
8. A synthesis process for trityl olmesartan medoxomil according to claim 1, characterized in that: In the trityl olmesartan medoxomil synthesis step, the weak acid salt includes one or more of potassium carbonate, potassium acetate, and sodium carbonate.
9. A synthesis process for trityl olmesartan medoxomil according to claim 1, characterized in that: In the trityl olmesartan medoxomil synthesis step, the catalyst includes one or more of potassium iodide, sodium iodide, and sodium chloride.
10. A synthesis process for trityl olmesartan medoxomil according to claim 1, characterized in that: In the trityl olmesartan medoxomil synthesis step, when the filtrate is purified by column chromatography, the eluent includes a mixture of petroleum ether and ethyl acetate.
